Bristol Myers will buy Karuna for about 14 billion dollars

Bristol Myers to buy Karuna Therapeutics for $14B. Karuna's crown jewel, an experimental drug called KarXT, is the product of such new insights. The drug could surpass $6 billion in yearly sales if it is approved for the various uses.

Bristol Myers to buy RayzeBio for about $4.1B. The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Bristol Myers: "Two of our top blood cancer treatments face generic competitors"